Back to School: How biopharma can reboot drug development. Access exclusive analysis here

0910 Casma EMB 0910 midnight ET
BioCentury & Getty Images

Finance

Casma to advance muscle dystrophy candidate into the clinic with $50M series B

Sep 10, 2020 | 5:12 PM GMT

A $50 million series B round led by The Column Group will provide Casma with enough cash to bring its lead Duchenne

Read the full 513 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE